See more : ARYx Therapeutics, Inc. (ARYX) Income Statement Analysis – Financial Results
Complete financial analysis of Arcturus Therapeutics Holdings Inc. (ARCT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Arcturus Therapeutics Holdings Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Cineworld Group plc (CINE.L) Income Statement Analysis – Financial Results
- AMTD Digital Inc. (HKD) Income Statement Analysis – Financial Results
- Fatfish Group Limited (FFG.AX) Income Statement Analysis – Financial Results
- UnipolSai Assicurazioni S.p.A. (UNPLF) Income Statement Analysis – Financial Results
- Brigadier Gold Limited (BRG.V) Income Statement Analysis – Financial Results
Arcturus Therapeutics Holdings Inc. (ARCT)
About Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 157.75M | 205.76M | 12.36M | 9.54M | 20.79M | 15.75M | 13.00M | 20.38M | 6.14M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 2.96M | 143.05M | 171.86M | 55.95M | 32.44M | 16.98M | 410.00K | 294.00K | 51.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 154.79M | 62.70M | -159.50M | -46.41M | -11.65M | -1.23M | 12.59M | 20.09M | 6.09M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 98.13% | 30.48% | -1,290.57% | -486.50% | -56.04% | -7.80% | 96.85% | 98.56% | 99.17% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 192.13M | 147.75M | 173.76M | 57.85M | 33.64M | 16.98M | 15.92M | 18.39M | 13.46M | 25.11M | 7.07M | 818.00K | 1.82M |
| General & Administrative | 52.87M | 46.07M | 41.45M | 23.22M | 12.66M | 20.58M | 7.57M | 5.36M | 4.99M | 5.84M | 3.22M | 683.00K | 2.08M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 52.87M | 46.07M | 41.45M | 23.22M | 12.66M | 20.58M | 7.57M | 5.36M | 4.99M | 5.84M | 3.22M | 683.00K | 2.08M |
| Other Expenses | 0.00 | -244.00K | 0.00 | 0.00 | 0.00 | 0.00 | -348.00K | 1.42M | 1.25M | 2.13M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 235.95M | 193.58M | 215.21M | 81.06M | 46.30M | 37.56M | 23.49M | 25.17M | 19.70M | 33.08M | 10.29M | 1.50M | 3.91M |
| Cost & Expenses | 245.00M | 193.58M | 215.21M | 81.06M | 46.30M | 37.56M | 23.49M | 25.17M | 19.70M | 33.08M | 10.29M | 1.50M | 3.91M |
| Interest Income | 17.36M | 2.58M | 753.00K | 470.00K | 408.00K | 514.00K | 89.00K | 798.00K | 338.00K | 239.00K | 22.00K | 2.00K | 21.00K |
| Interest Expense | 767.00K | 420.00K | 2.67M | 361.00K | 446.00K | 186.00K | 150.00K | 295.00K | 251.00K | 2.00K | 197.00K | 80.00K | 44.00K |
| Depreciation & Amortization | 2.96M | 1.53M | 1.19M | 882.00K | 684.00K | 582.00K | 410.00K | 294.00K | 51.00K | 31.00K | 8.00K | 7.00K | 6.00K |
| EBITDA | -24.17M | 13.70M | -201.66M | -70.64M | -24.42M | -20.72M | -10.34M | -947.00K | -1.72M | -32.81M | -10.28M | -1.51M | -3.92M |
| EBITDA Ratio | -15.32% | 5.67% | -1,621.42% | -752.56% | -122.88% | -133.42% | -79.56% | -123.18% | -320.09% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -78.21M | 12.18M | -202.85M | -71.52M | -25.51M | -21.81M | -10.49M | -25.17M | -19.70M | -33.08M | -10.29M | -1.50M | -3.91M |
| Operating Income Ratio | -49.58% | 5.92% | -1,641.33% | -749.81% | -122.72% | -138.46% | -80.72% | -123.48% | -320.92% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 50.32M | -1.53M | -822.00K | -624.00K | -478.00K | 26.00K | -409.00K | -536.00K | 11.00K | 227.00K | -197.00K | -78.00K | -23.00K |
| Income Before Tax | -27.89M | 10.64M | -203.67M | -72.15M | -25.99M | -21.79M | -10.90M | -24.53M | -19.40M | -32.85M | -10.49M | -1.58M | -3.93M |
| Income Before Tax Ratio | -17.68% | 5.17% | -1,647.98% | -756.35% | -125.02% | -138.29% | -83.87% | -120.35% | -316.03% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 1.84M | 1.30M | 3.19M | -784.00K | -270.00K | 212.00K | 1.00K | 73.00K | 51.00K | -17.00K | 61.00K | 65.00K | 21.00K |
| Net Income | -29.73M | 9.35M | -206.86M | -71.36M | -25.72M | -21.79M | -10.90M | -24.60M | -19.45M | -32.83M | -10.55M | -1.58M | -3.93M |
| Net Income Ratio | -18.84% | 4.54% | -1,673.78% | -748.13% | -123.72% | -138.29% | -83.87% | -120.71% | -316.86% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.12 | 0.35 | -7.86 | -3.51 | -2.13 | -2.16 | -3.53 | -6.25 | -6.29 | -16.81 | -7.25 | -0.99 | -2.47 |
| EPS Diluted | -1.12 | 0.35 | -7.86 | -3.51 | -2.13 | -2.16 | -3.53 | -6.25 | -6.29 | -16.81 | -7.25 | -0.99 | -2.47 |
| Weighted Avg Shares Out | 26.63M | 26.45M | 26.32M | 20.31M | 12.07M | 10.07M | 3.09M | 3.94M | 3.09M | 1.95M | 1.45M | 1.59M | 1.59M |
| Weighted Avg Shares Out (Dil) | 26.63M | 27.09M | 26.32M | 20.31M | 12.07M | 10.07M | 3.09M | 3.94M | 3.09M | 1.95M | 1.45M | 1.59M | 1.59M |
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
KING OF PRUSSIA, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics (Nasdaq: ARCT) today announced the results of a follow-up analysis of a Phase 3 study evaluating a booster dose of ARCT-154, the...
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
Study conducted by Meiji Seika Pharma in Japan Short communication follows previously published data in The Lancet Infectious Diseases demonstrating Immunological Non-Inferiority to Wuhan Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster Ne w data demonstrates...
Why Arcturus Therapeutics Has A Promising Future With Innovative CF And COVID Treatments
Arcturus Therapeutics is a biotechnology company specializing in rare and infectious diseases, with approved COVID and influenza vaccines in Japan and the EU. The company is developing game-changing therapies for Ornithine Transcarbamylase Deficiency and Cystic Fibrosis. Despite trading at a...
Arcturus: H1 2024 Rare Disease Drug Data On Deck
Arcturus Therapeutics Holdings Inc. interim results from the phase 1b study, using ARCT-032 for the treatment of patients with Cystic Fibrosis, are expected in the 1st half of 2024. The global Cystic Fibrosis market is projected to grow to $12.9...
CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
KING OF PRUSSIA, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics (Nasdaq: ARCT) today announced the publication in Lancet Infectious Diseases of a Phase 3 study showing that a booster dose of ARCT-154,...
CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
Study conducted by Meiji Seika Pharma in Japan Data follow approval of the world's first self-amplifying messenger RNA (sa-mRNA) COVID-19 vaccine for adults by Japan Ministry of Health, Labor and Welfare The randomized, double-blind, active-controlled study, conducted at 11 sites in...
7 Undervalued Biotech Stocks That are Flying Under the Clinical Radar
With so many innovative firms skyrocketing this year, astute investors seeking compelling discounts may want to turn their attention to undervalued biotech picks. Just like advancements in the digital ecosystem, society will continue to invest in clinical breakthrough stocks in...
3 Biotech Stocks With Promising Pipelines and Big Growth Potential in 2024
With such a high demand for items that can improve our longevity and health, biotechnology is at the forefront of today's innovation. Biotech products allow us to better understand the human body and how we can improve functioning within the...
Arcturus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced...
Arcturus' (ARCT) CF Drug Gets FDA's Orphan Status, Stock Up
Arcturus (ARCT) rises 8% as the FDA grants Orphan Drug Designation for its product candidate, ARCT-032, for the treatment of cystic fibrosis.
Source: https://incomestatements.info
Category: Stock Reports